Swedish Orphan Biovitrum - About the company
Swedish Orphan Biovitrum is an acquired company based in Stockholm (Sweden), founded in 1988. It operates as a Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases. Swedish Orphan Biovitrum has raised an undisclosed amount in funding. The company has 280 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.
Company Details
Swedish Orphan Biovitrum is a biopharmaceutical company that develops drugs for rare diseases like Haemophilia, Inflammation, and Genetic diseases. Its lead product ELOCTA (rFVIIIFc) is used for treating hemophilia. Its other lead product ALPROLIX (rFIXFc) for hemophilia B. It has other pipeline drugs for Tyrosinaemia Alkaptonuria which are in regulatory review and for enzyme replacement therapy which is in the pre-clinical phase.
- Website
- www.sobi.com/en
- Registered Address
- Waltham, Massachusetts
Key Metrics
Founded Year
1988
Location
Stockholm, Sweden
Stage
Acquired
Latest Funding Round
Investors
Ranked
26th among 280 active competitors
Employee Count
2,425 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Acquired by Advent International (Sep 02, 2021)
Legal entities associated with Swedish Orphan Biovitrum
Swedish Orphan Biovitrum is associated with 3 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Romania s.r.o. CIN: 63505312 , Czech Republic, Active | Apr 10, 1995 | - | - | |
SABI INTERNATIONAL s.r.o. CIN: 26164027 , Czech Republic, Active | Mar 15, 2000 | - | - | |
SOBI, INC CIN: 680682244 , United States, Active | Dec 26, 999 | - | 467 (As on Dec 31, 2024) | - |
Swedish Orphan Biovitrum's acquisition details
Swedish Orphan Biovitrum got acquired by Advent International and GIC on Sep 02, 2021.
Click here to take a look at Swedish Orphan Biovitrum's acquisition in detail
Sign up to download Swedish Orphan Biovitrum's company profile
Swedish Orphan Biovitrum's funding and investors
Swedish Orphan Biovitrum has raised funding over 3 rounds. Its first funding round was on 2006. Its latest funding round was a Post IPO round on Oct 31, 2023 for $*****. 1 investor participated in its latest round. Swedish Orphan Biovitrum has 5 institutional investors.
Here is the list of recent funding rounds of Swedish Orphan Biovitrum:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Oct 31, 2023 | 2806840 | Post IPO | 9510417 | 2202980 | 1681337 | 5054859 |
Sep 30, 2019 | 7129471 | Conventional Debt | 8528452 | 5250124 | 6986861 | 7716656 |
2006 | 7798 | Post IPO | 4816 | 6377 | 1164 |
Access funding benchmarks and valuations. Sign up today!View details of Swedish Orphan Biovitrum's funding rounds and investors
Swedish Orphan Biovitrum's founders and board of directors
Founder? Claim ProfileSwedish Orphan Biovitrum's employee count trend
Swedish Orphan Biovitrum has 2,425 employees as of Sep 26. Here is Swedish Orphan Biovitrum's employee count trend over the years:
Uncover Swedish Orphan Biovitrum's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Swedish Orphan Biovitrum's Competitors and alternates
Top competitors of Swedish Orphan Biovitrum include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Swedish Orphan Biovitrum, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  BridgeBio 2015, Palo Alto (United States), Public | Developer of therapeutics for the treatment of genetic diseases | $434M | 81/100 | |
2nd | Alnylam 2002, Cambridge (United States), Public | Developer of RNA interference-based therapeutics for multiple disorders | $17M | 79/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 74/100 | |
5th | Spark Therapeutics 2013, Philadelphia (United States), Acquired | Developer of gene therapy for rare diseases | $82.8M | 73/100 | |
6th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 71/100 | |
7th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 71/100 | |
8th | Agios Pharmaceuticals 2008, Cambridge (United States), Public | Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism | $120M | 70/100 | |
9th | Rhythm Pharmaceuticals 2010, Boston (United States), Public | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | $84M | 70/100 | |
10th | Regenxbio 2008, Rockville (United States), Public | Developer of AAV Gene Therapy for rare genetic diseases | $108M | 67/100 | |
26th | Swedish Orphan Biovitrum 1988, Stockholm (Sweden), Acquired | Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases | - | 62/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Swedish Orphan Biovitrum's competitors? Click here to see the top ones
Swedish Orphan Biovitrum's Investments and acquisitions
Swedish Orphan Biovitrum has not made any investments yet. Swedish Orphan Biovitrum has made 4 acquisitions.Here is the list of latest three $acquisitions:
Filter this list
Filter this listDate of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Dec 14, 2025 | Acquisition | 2017 | Irvine (United States) | |
May 10, 2023 | Acquisition | 1991 | Seattle (United States) | |
Sep 30, 2019 | Acquisition | 2016 | Durham (United States) |
Want to know more about where corporates are investing? Sign up today!See all acquisitions by Swedish Orphan Biovitrum
Reports related to Swedish Orphan Biovitrum
Here is the latest report on Swedish Orphan Biovitrum's sector:
News related to Swedish Orphan Biovitrum
Filter this listMedia has covered Swedish Orphan Biovitrum for a total of 40 events in the last 1 year, 10 of them have been about company updates and 4 about partnerships.
•
Börje Ekholm Proposed as New Chair of Sobi Board of DirectorsPR Newswire•Oct 30, 2026•Swedish Orphan Biovitrum
•
Swedish Orphan Biovitrum AB (publ) (SWOBY) Q3 2026 Earnings Call TranscriptSeeking Alpha•Oct 28, 2026•Swedish Orphan Biovitrum
•
Sobi Q3 2026 Report: Strong Growth Momentum Driven by Haematology RevenuePR Newswire•Oct 27, 2026•Swedish Orphan Biovitrum
•
Sobi to Present Clinical Data on Gamifant® at Histiocyte Society 2026PR Newswire•Sep 24, 2026•Swedish Orphan Biovitrum
•
Sobi and Innate Pharma Announce Strategic Partnership Effective Following Closing ConditionsCision•Sep 17, 2026•Innate Pharma, Swedish Orphan Biovitrum, Innateindia
•
Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS SyndromeGlobeNewswire•Sep 09, 2026•Swedish Orphan Biovitrum
•
•
Innate Pharma Advances Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical OfficerWebDisclosure•Aug 10, 2026•Innate Pharma, Swedish Orphan Biovitrum, Kymos, Lymphoma
•
Sobi Aktie: Lizenzdeal mit Innate PharmaAd Hoc News•Aug 10, 2026•Innate Pharma, Swedish Orphan Biovitrum
•
Sobi's Board Authorizes Share Repurchase to Fulfill Incentive Program CommitmentsPR Newswire•Jul 16, 2026•Swedish Orphan Biovitrum
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Swedish Orphan Biovitrum
Explore our recently published companies
- Solar - Indore based, 1994 founded, Unfunded company
- Bina Punjani - India based, 2011 founded, Unfunded company
- Aviator - India based, Unfunded company
- Admit Beacon - India based, 2021 founded, Unfunded company
- Origin Itfs - Chennai based, 1993 founded, Unfunded company
- 1Win - India based, 2026 founded, Unfunded company
